Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.

Source:http://linkedlifedata.com/resource/pubmed/id/2137327

Download in:

View as

General Info

PMID
2137327